Latest News

Latest News

The Financial Infrastructure Behind Healthcare Innovation

The Financial Infrastructure Behind Healthcare Innovation

Healthcare is changing faster than I have ever seen it change, and the revenue cycle has to keep pace. We are talking about AI, new treatments, new technology, new specialties and entirely new ways of delivering care. All of that is exciting, and much of it has the...

read more
When the Model Is Confident and the Patient Is Not

When the Model Is Confident and the Patient Is Not

It is 2:07 a.m. in the emergency department. The waiting room is thin. The hallway is not. A middle-aged man looks pale. His vitals sit in the green band. A clinical decision support tile on the chart says low risk with a high confidence score. His wife keeps saying...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Climate-Sensitive Maternal Mental Health Screening

Climate-Sensitive Maternal Mental Health Screening

A pregnant woman may never walk into a clinic saying climate change is affecting her mental health. She may say she has not slept through the heat. She may say flooding made her miss an antenatal visit. She may say food costs have changed what she can feed her family....

read more
Biotech’s Missing Ingredient: Execution

Biotech’s Missing Ingredient: Execution

Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients.  Over the last several years, I have seen strong assets struggle for reasons...

read more
Weekly News Roundup | 25 May 2026

Weekly News Roundup | 25 May 2026

Life science news 25 May 2026: Lilly's retatrutide delivers bariatric-surgery-level weight loss in Phase 3, two landmark FDA approvals reshape oncology and hepatology, and a UK biotech targets the global AMR crisis. The week of 17 to 24 May 2026 delivered a dense...

read more
Clinical Trials Roundup | 22 May 2026

Clinical Trials Roundup | 22 May 2026

Merck's sacituzumab tirumotecan meets both primary endpoints in the pivotal Phase 3 TroFuse-005 trial for advanced endometrial cancer, Relay Therapeutics reports the first clinical evidence of PI3Kα mutant-selective inhibition in PIK3CA-driven vascular anomalies in...

read more
Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift

Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift

The arrival of two approved oral GLP-1 weight loss therapies in the space of four months has fundamentally redrawn the obesity treatment landscape in 2026. For years, the question of whether a daily pill could ever match the efficacy of a weekly injection was largely...

read more
Climate-Sensitive Maternal Mental Health Screening

Climate-Sensitive Maternal Mental Health Screening

A pregnant woman may never walk into a clinic saying climate change is affecting her mental health. She may say she has not slept through the heat. She may say flooding made her miss an antenatal visit. She may say food costs have changed what she can feed her family....

read more
Biotech’s Missing Ingredient: Execution

Biotech’s Missing Ingredient: Execution

Biotech has never lacked scientific innovation. What the industry continues to underestimate is how difficult it is to turn promising science into an actual therapy that reaches patients.  Over the last several years, I have seen strong assets struggle for reasons...

read more
Weekly News Roundup | 25 May 2026

Weekly News Roundup | 25 May 2026

Life science news 25 May 2026: Lilly's retatrutide delivers bariatric-surgery-level weight loss in Phase 3, two landmark FDA approvals reshape oncology and hepatology, and a UK biotech targets the global AMR crisis. The week of 17 to 24 May 2026 delivered a dense...

read more
Clinical Trials Roundup | 22 May 2026

Clinical Trials Roundup | 22 May 2026

Merck's sacituzumab tirumotecan meets both primary endpoints in the pivotal Phase 3 TroFuse-005 trial for advanced endometrial cancer, Relay Therapeutics reports the first clinical evidence of PI3Kα mutant-selective inhibition in PIK3CA-driven vascular anomalies in...

read more
Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift

Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift

The arrival of two approved oral GLP-1 weight loss therapies in the space of four months has fundamentally redrawn the obesity treatment landscape in 2026. For years, the question of whether a daily pill could ever match the efficacy of a weekly injection was largely...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Why Neurology Clinical Trials Need Purpose-Built AI

Why Neurology Clinical Trials Need Purpose-Built AI

Each year on May 20, International Clinical Trials Day recognizes James Lind’s 1747 scurvy trial and the patients, clinicians, coordinators, sponsors and researchers who make clinical progress possible. It is also a moment to look honestly at where clinical research...

read more
What the Veppanu Approval Means for ESR1 Breast Cancer

What the Veppanu Approval Means for ESR1 Breast Cancer

The FDA's approval of Veppanu (vepdegestrant) marks the first regulatory clearance for a PROTAC in any disease area, and opens a new chapter in the treatment of ESR1-mutated advanced breast cancer. On 1 May 2026, the United States Food and Drug Administration approved...

read more
Agentic AI in Drug Discovery: Why Big Pharma is All in

Agentic AI in Drug Discovery: Why Big Pharma is All in

When Eli Lilly signed a deal worth up to $2.75 billion with AI drug developer Insilico Medicine in March 2026, it was the latest in a cascade of nine-figure and ten-figure commitments from the world’s largest pharmaceutical companies to a single emerging technology....

read more
Why Biopharma Must Invest in Novel Targets

Why Biopharma Must Invest in Novel Targets

Drug development continues to concentrate on a small set of well-known targets, creating a crowded landscape where many companies pursue similar pathways. While research into novel mechanisms continues, familiar targets often take priority, reflecting a cautious...

read more
Weekly News Roundup | 18 May 2026

Weekly News Roundup | 18 May 2026

Life science news 18 May 2026: FDA leadership turmoil, a landmark Alzheimer's breakthrough and a $15 billion China licensing deal define a historic week for the global industry. The week of 10 to 17 May 2026 delivered a concentration of high-impact events across...

read more
Biologics on the Brink: The Patent Cliff Facing Big Pharma

Biologics on the Brink: The Patent Cliff Facing Big Pharma

The global pharmaceutical industry is approaching what many analysts are calling the largest patent cliff biologics in its history. This pharma patent cliff biologics analysts have long anticipated is now arriving in force. Between 2025 and 2030, drugs collectively...

read more
Clinical Trials Roundup | 15 May 2026

Clinical Trials Roundup | 15 May 2026

AstraZeneca's eneboparatide meets the Phase 3 CALYPSO primary endpoint in chronic hypoparathyroidism with full data presented at the European Congress of Endocrinology, Alkermes' LUMRYZ meets its primary endpoint in the Phase 3 REVITALYZ trial for idiopathic...

read more

Further News

Creative Biolabs’ CRISPR Cell Line Development: Plan the Validation First

CRISPR has expanded the possibilities for creating genetically defined cell models, from loss-of-function knockouts to precise knock-ins and stable Cas9-expressing systems. However, successful CRISPR cell line development depends on more than editing efficiency. The...

Autogene Cevumeran Halt Redraws Cancer Vaccine Trial Design

BioNTech and Genentech have stopped a Phase 2 trial of autogene cevumeran in colorectal cancer. An independent data safety monitoring board recommended the termination. The companies confirmed the decision on 28 August 2026. It arrives nine days after a landmark...

Brepocitinib Dermatomyositis Approval Breaks the Steroid-First Pattern

The brepocitinib dermatomyositis approval landed on 27 August 2026. It is the first shift in a treatment field that has barely moved in decades. The US Food and Drug Administration cleared LISRAYA, an oral dual TYK2 and JAK1 inhibitor, for adults with dermatomyositis....

Why Preventive Foot Care Should Be Central to Diabetes Management

Podiatric input is still mostly reactive, despite the significant advancements in diabetes care in recent decades. All too frequently, patients are referred to podiatry only after infections or ulcers have already occurred. This reactive approach is expensive in terms...

Clinical Trials Roundup | 28 Aug 2026

Revolution Medicines’ Rasonque receives FDA approval as what the FDA calls the first in class targeted therapy for metastatic pancreatic cancer, Priovant’s Lisraya is cleared as the first oral therapy indicated for dermatomyositis in adults, Johnson & Johnson’s...

From EHR Data to Real-World Evidence: Health IT Meets R&D

For most of their existence, electronic health records have been treated as administrative infrastructure, a place to document a visit, justify a claim and satisfy a compliance requirement. That framing no longer reflects their potential. The same records that...

Daraxonrasib FDA Approval Sets a New Bar in Pancreatic Cancer

The daraxonrasib FDA approval, granted on 26 August 2026, gives metastatic pancreatic cancer its first approved targeted therapy. Revolution Medicines will sell the drug as Rasonque. The agency cleared it roughly six and a half months ahead of its goal date. For an...

When Meditation Meets the Page: Can Writing Help Us Understand the Mind?

Meditation may help us observe an experience without immediately reacting to it. Expressive writing may help us give that experience language, structure and meaning. What happens when we stop trying to escape an uncomfortable thought or emotion and instead observe it...

Oral GLP-1 Manufacturing: Can Supply Meet Demand?

Oral GLP-1 manufacturing is now the binding constraint in obesity, not patient acceptance. The question is peptide capacity, tabletting lines and capital committed ahead of demand. Two weight loss tablets have reshaped the obesity market in under a year. Novo...

Zanidatamab Approval Resets First-Line HER2 Gastric Cancer Care

The US Food and Drug Administration cleared two zanidatamab regimens on 25 August 2026. The zanidatamab approval covers first-line treatment of HER2-positive advanced gastro-oesophageal adenocarcinoma. It displaces trastuzumab from a first-line backbone that has...

Leverage Trauma-Informed Care to Enhance Adherence to Safety Interventions

Patient trauma can have a significant impact on the ways in which patients interact with the healthcare environment and with its staff. Many patient behaviors can stem from trauma, including lack of adherence to care plans. In the context of patient safety,...

Robotic Gastrectomy Outperforms Laparoscopic Surgery in Japanese Study

Robotic gastrectomy delivers measurably better perioperative outcomes than conventional laparoscopic surgery for gastric cancer, according to a nationwide analysis of Japanese surgical practice covering more than 22,000 patients. Gastric cancer is the fifth most...

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.

See More Articles

Want to Be Part of the Next Chapter in Life Sciences Media?

 

LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

 

 

Don’t wait for the media to pick up your story. Be the media.